한글목차

세계의 단백질 의약품 시장 규모는 2024년 4,417억 달러에서 2029년 말에는 6,557억 달러에 이를 것으로 예측되고 있으며, 2024-2029년 CAGR은 8.2%로 성장할 전망입니다.

북미 시장은 2024년에 2,359억 달러에서 2029년 말에는 3,469억 달러로 확대될 것으로 예상되며, 이 기간 CAGR 8.0%로 성장할 전망입니다. 유럽 시장은 2024년 1,152억 달러에서 2029년 말에는 1,661억 달러에 이를 전망이며, 예측 기간 중 CAGR은 7.6%로 성장이 예측되고 있습니다.

본 보고서에서는 세계의 단백질 의약품 시장을 조사했으며, 시장 개요, 시장 영향인자 및 시장 기회 분석, 법규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추이 및 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요기업 프로파일 등을 정리했습니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약

제2장 시장 개요

• 현재 및 미래 시장 개요
• 기술적 배경
• 치료용 단백질의 약리학적 분류
• 효소 활성 및 조절 활성을 갖는 단백질 치료제
• 특별한 표적 활성을 갖는 단백질 치료제
• 단백질 백신
• 치료용 단백질의 특성
• 거시경제 요인
• Porter's Five Forces 분석
• 공급망 분석

제3장 시장 역학

• 세계 시장 역학
• 시장 성장 촉진요인
• 제조 기술의 진보
• 지속적인 제품 출시
• 암 발생률 증가
• 시장 성장 억제요인
• 단백질 의약품의 고비용
• 복잡한 규제 절차
• 시장의 과제
• 특허 만료 및 독점권 상실
• 단백질 의약품의 안정성 및 전달
• 시장 기회
• MAb 승인 건수 증가
• 라이선싱 및 협업 계약

제4장 규제 상황

• 규제 시나리오
• 가격규제

제5장 신기술

• 개요
• 단백질 의약품 시장에서의 신기술
• 이중 특이성 항체 및 다중 특이성 항체
• 항체 약물 복합체
• 항체 융합 단백질
• 단백질 의약품 시장에서 AI

제6장 시장 부문 분석

• 개요
• 세분화의 내역
• 세계의 단백질 의약품 시장 : 유형별
• 단일클론항체
• 펩티드 호르몬
• 백신
• 혈액 인자
• 사이토카인
• 치료용 효소
• 펩티드 항생제
• 융합 단백질
• 세계의 단백질 의약품 시장 : 제조 기술별
• 세포 배양
• 미생물 발효
• 천연원
• 수정란
• 화학합성
• 트랜스제닉
• 지역별 시장 분석
• 세계의 단백질 의약품 시장 : 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제7장 경쟁 정보

• 산업 구조
• 주요 단백질 의약품(2023년)
• 시장 점유율 분석
• 단일클론항체
• 펩티드 호르몬
• 전략 분석
• 인수
• 제품 승인
• 협정 및 파트너십
• 기타 전략

제8장 단백질 의약품 시장에서 지속가능성 : ESG의 관점

• 단백질 의약품 업계에서 지속가능성
• ESG 위험 평가 : 데이터 이해
• ESG 성능 분석
• 환경 성능
• 사회적 퍼포먼스
• 거버넌스 퍼포먼스
• 총론

제9장 부록

• 조사 방법
• 약어
• 참고문헌
• 기업 프로파일
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.

영문목차

The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

The North American protein drugs market is expected to grow from $235.9 billion in 2024 and is projected to reach $346.9 billion by the end of 2029, at a CAGR of 8.0% during the forecast period of 2024 to 2029.

The European protein drugs market is expected to grow from $115.2 billion in 2024 and is projected to reach $166.1 billion by the end of 2029, at a CAGR of 7.6% during the forecast period of 2024 to 2029.

Report Scope

The report analyzes trends in the global market for protein drugs and manufacturing technologies. The report includes global revenue ($ millions) for the base year of 2023 and estimated data for the forecast period of 2024 through 2029. The market is segmented by product type/subtype, manufacturing technology and region. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.

The report focuses on the trends and challenges that affect the market and the vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the rankings and market shares of leading companies in the protein drug market. It also has a section of company profiles that shows financials, product portfolios and recent developments.

Report Includes

• 79 data tables and 57 additional tables
• An analysis of the global markets for protein drugs and their manufacturing technologies
• Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the size of and revenue prospects for the global market, along with a market share analysis by type of protein drug, manufacturing technology, and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Analysis of the advances in manufacturing technologies, disease prevalence trends, new products , and the impact of biosimilars entering the market for protein drugs
• An analysis of patents and significant patent grants
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of leading companies, including AbbVie Inc., Bristol Myer Squibb, Merck & Co., Novo Nordisk S/A, Sanofi, and Roche

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Current and Future Market Overview
• Technology Background
• Pharmacological Classification of Therapeutic Proteins
• Protein Therapeutics with Enzymatic or Regulatory Activity
• Protein Therapeutics with Special Targeting Activity
• Protein Vaccines
• Characteristics of Therapeutic Proteins
• Macroeconomic Factors
• Porter's Five Forces Analysis
• Potential for New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Competition in the Industry
• Supply Chain Analysis
• R&D
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies/Hospitals
• Dispensed to Consumers

Chapter 3 Market Dynamics

• Global Market Dynamics
• Market Drivers
• Advances in Manufacturing Technologies
• Continuous Product Launches
• Increasing Incidence of Cancer
• Market Restraints
• High Costs of Protein Drugs
• Complex Regulatory Procedures
• Market Challenges
• Patent Expiration and Loss of Exclusivity
• Protein Drugs Stability and Delivery
• Market Opportunities
• Increasing Number of Approvals for MAbs
• Licensing and Collaboration Agreements

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• Price Regulations

Chapter 5 Emerging Technologies

• Overview
• Emerging Technologies in Protein Drugs Market
• Bispecific Antibodies and Multi-Specific Antibodies
• Antibody-Drug Conjugates
• Antibody Fusion Proteins
• AI in the Protein Drug Market

Chapter 6 Market Segment Analysis

• Overview
• Segmentation Breakdown
• Global Market for Protein Drugs, by Type
• MAbs
• Peptide Hormones
• Vaccines
• Blood Factors
• Cytokines
• Therapeutic Enzymes
• Peptide Antibiotics
• Fusion Proteins
• Global Market for Protein Drugs, by Manufacturing Technology
• Cell Culture
• Microbial Fermentation
• Natural Source
• Embryonated Egg
• Chemical Synthesis
• Transgenics
• Market Breakdown by Region
• Global Market for Protein Drugs, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Industry Structure
• Leading Protein Drugs, 2023
• Market Share Analysis
• MAbs
• Peptide Hormones
• Strategic Analysis
• Acquisitions
• Product Approvals
• Agreements and Partnerships
• Other Strategies

Chapter 8 Sustainability in the Protein Drug Market: ESG Perspective

• Sustainability in the Protein Drug Industry
• ESG Risk Ratings: Understanding the Data
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Abbreviations
• References
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.